Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.
Emily Comstock, Charles Fogarty, Jorge Caso et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized trial assessed the safety and immunogenicity of the mRNA-1345 RSV vaccine coadministered with high-dose quadrivalent influenza vaccine in adults aged 65 and older (n=1900). The study found that coadministration demonstrated noninferiority for influenza immune responses, with geometric mean ratios of anti-hemagglutinin titers between 0.868 and 0.948. However, noninferiority for RSV responses was not achieved.
Key findings
- Noninferiority for influenza A and B immune responses was demonstrated with GMRs of 0.868-0.948.
- Lower bounds of the 95% CI for influenza responses were all >0.667, meeting noninferiority criteria.
- Noninferiority for RSV-A and RSV-B was not demonstrated, with GMRs of 0.625 and 0.638, respectively.
- Coadministration is estimated to maintain mRNA-1345 efficacy against RSV-lower respiratory tract disease.
Why it matters
The findings suggest that coadministering RSV and influenza vaccines may enhance vaccination rates in older adults, a population at high risk for severe respiratory infections. Understanding the immunogenicity of combined vaccination strategies is crucial for optimizing preventive measures.